Skip to main content

Advertisement

Table 3 Risk factors for survival and GVHD: Cox regression analysis

From: Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study

Risk factor Relative risk 95% CI P value
II–IV aGVHD
 Patient age < 20 years vs. ≥ 20 years 1.863 1.300–2.668 0.001
 HLA 3/6 vs. 5–6/6 4.702 1.161–19.037 0.030
 HLA 3/6 vs. 4/6 1.509 0.906–2.512 0.114
III–IV aGVHD
 Patient age < 20 years vs. ≥ 20 years 2.316 1.081–4.962 0.031
 ABO minor mismatch vs. others 2.817 1.438–5.519 0.003
cGVHD
 Mother donor vs. father donor 1.804 1.069–3.044 0.027
Overall survival
 Male to female vs. others 0.433 0.210–0.889 0.023
 Months from diagnosis to transplant ≥ 12 vs. < 12 1.876 1.057–3.328 0.032
 ECOG 2–3 vs. 0–1 3.605 2.028–6.409 0.000
 MNC 6–10 × 108/kg vs. others 0.440 0.249–0.778 0.005
Failure-free survival
 Months from diagnosis to transplant ≥ 12 vs. < 12 1.907 1.124–3.235 0.017
 ECOG 2-3 vs. 0-1 2.388 1.414–4.032 0.001
GVHD-free/relapse-free survival
 ABO minor mismatch vs. others 1.856 1.245–2.765 0.002
 ECOG 2–3 vs. 0–1 1.589 1.016–2.486 0.043
 MNC 6–10 × 108/kg vs. others 0.642 0.433–0.953 0.028
  1. aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, ECOG Eastern Cooperative Oncology Group, MNC mononuclear cell